Nordicus Partners to Reincorporate in Nevada, Authorized Common Stock Rises Ninefold to 450M
NORD has more than doubled off its 52-week low of $1.25 on elevated volume (3.4× avg).
Summary
Nordicus Partners will convert from Delaware to Nevada and rename itself Nordicus Biotech Corporation, raising authorized common stock from 50 million to 450 million shares. The conversion itself is one-for-one with no business change, but the added issuance capacity matters for a company already flagged with going-concern doubt.
Key Events · Corporate Governance and Compliance · NORD
-
Nevada Reincorporation Approved by Written Consent
Holders of 12,793,464 shares, about 63.3% of voting power, consented on November 12, 2026 to convert the company from Delaware to Nevada and rename it Nordicus Biotech Corporation. The action takes effect no earlier than 20 days after the information statement is mailed.
-
Authorized Common Stock Raised Ninefold
The Nevada charter authorizes 450,000,000 common shares versus 50,000,000 today, and 50,000,000 preferred versus 5,000,000. Against 20,201,538 shares outstanding, that is roughly 430 million shares of unissued common the board can sell without a stockholder vote.
-
Minority Protections Reduced
The company opts out of Nevada's business-combination statutes (NRS 78.411-78.444) and control-share statutes (NRS 78.378-78.3793), and the Nevada charter adds officer exculpation that the Delaware charter did not have. Nevada bylaws also drop the advance-notice and exclusive-forum provisions.
-
No Change to Business or Share Count
Each outstanding share converts into one share of the Nevada corporation, options and warrants carry over on the same terms, and the stock keeps trading on Nasdaq under NORD. Management, directors and operations are unchanged.
Analysis · NORD · Trade & Services
A 63.3% stockholder bloc has approved moving the company's domicile from Delaware to Nevada and renaming it Nordicus Biotech Corporation, with no change to the business, management or the one-for-one share conversion. The real substance lies in the charter: authorized common stock jumps from 50,000,000 to 450,000,000 shares and preferred from 5,000,000 to 50,000,000, all issuable by the board without a further stockholder vote. Against 20,201,538 shares outstanding, that leaves roughly 430 million shares of issuance headroom — a company that just posted a going-concern warning and has been funding itself through small convertible notes and insider loans now has a much larger toolkit to dilute. The company also opts out of Nevada's business-combination and control-share statutes, removing statutory moratorium protections minority holders currently have under Delaware law.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NORD was trading at $2.87 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $55.8M. The 52-week trading range was $1.25 to $6.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.